Wearable muscle fiber excitation system for preventing blood clot

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43MH101892-01
Agency Tracking Number: R43MH101892
Amount: $350,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solitcitation Year: 2013
Solitcitation Topic Code: NIMH
Solitcitation Number: PA12-088
Small Business Information
GRADIENT BIOMODELING, LLC
8040 JUNIPER DRIIVE, PARK CITY, UT, 84098-
Duns: 831339564
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MARTIN MARTINOV
 (202) 640-9576
 martinov.mn@gradientbiomodeling.com
Business Contact
 NICK KALUDOV
Phone: (202) 640-9576
Email: kaludov.n@gradientbiomodeling.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype. It is probably one of the most costly psychiatric illnesses, yet the development of novel and safe antipsychotics lags behind. Amplifying the actions of endocannabinoids by inhibiting their enzymatic degradation has emerged as an alternative strategy to exploit the endocannabinoid system for possible clinical benefit. Here, we propose to apply a quantum-similarity approach to discover novel modulators (inhibitors) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), aiming to elevate endocannabinoid tone to relieve the negative symptoms of schizophrenia. Instead of blindly screening millions of compounds for novelmodulators of the target of interest, our focused testing of 10-20 commercially available compounds per target (pathway, protein etc.) with predicted (inhibitory) activity by the modeling effort, allows us to quickly explore novel chemical spaces for therapeutic applications, specifically and accurately targeting elusive, hard to modulate protein- protein interactions previously considered unapproachable by current discovery methods. The modeling, virtual search, identification and rank ordering of novel classes of FAAH and MAGL inhibitors, as well as the de novo design of novel antipsychotics will be done by Gradient Biomodeling. The in vitro and in vivo experimental evaluation of the compounds will be done in the laboratory of Dr. Andrea Giuffrida, at theUniversity of Texas Health Science Center at San Antonio. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype. It is one of the most costly psychiatric illnesses, not only in terms of direct cost but also as a result of its long-term impact and loss of productivity, requirig intensive medical psychiatric care as well as the indefinite need for social and economic support. Here, we propose to apply a quantum-similarity approach to discover novel modulators (inhibitors) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), aiming to elevate endocannabinoid tone to relieve the negative symptoms of schizophrenia.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government